Home LiteratureArticle Details
PMID: 20548049 Published · ppublish English Letter Research Support, N.I.H., Extramural Comment

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Neurology ·Vol. 74 ·No. 24 ·2010-06-15 ·Pages 2026; author reply 2026-7

Laskowitz DT, Kolls BJ

Abstract

暂无摘要

MeSH Terms
Alzheimer Disease/diagnosis,drug therapy,genetics Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Apolipoprotein E4/genetics Clinical Trials, Phase II as Topic/methods Dose-Response Relationship, Drug Humans
Chemicals
Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Apolipoprotein E4 bapineuzumab
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Laskowitz Daniel T
Kolls Brad J
Article Info
Journal
Neurology
Abbr.
Neurology
ISSN
1526-632X
DOI
10.1212/WNL.0b013e3181e03844
Published
2010-06-15
Pages
2026; author reply 2026-7
Language
English
Region
United States
NLM ID
0401060
Subset
IM
Grants
NINDS NIH HHS · 1R41NS056856 · United States
NINDS NIH HHS · R34NS06465 · United States
Corrections
CommentOn
PMID: 19923550
External Links
PubMed source DOI: 10.1212/WNL.0b013e3181e03844 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2